Open archive
Clear filters
Showing 1-6 of 6 published briefings.
Company archive
Read that company's published results in release order, newest first.
Showing 1-6 of 6 published briefings.
Pre-lease FCF turned negative at NZ$5.0m as capex rose and debtors built, even with biological performance lifting EBITDA to NZ$24.0m.
Published 26 May 2026
Read briefingOperating cash flow rose 21.2% to $19.6m, but volumes fell 17% and FY26 pro-forma EBITDA guidance of just $1-7m points to genuine operating pressure.
Published 23 April 2026
Read briefingHeadline NPAT fell on a $7.7m fair-value loss on biological assets versus a $15.8m prior gain, while operating cash flow nearly tripled to $38.5m.
Published 23 April 2026
Read briefingA $7.7m non-cash biological-asset/inventory swing pulled GAAP earnings down even as volumes, revenue and the company's guided pro-forma measure
Published 23 April 2026
Read briefingReported NPAT of $28.5m is flattered by a $15.8m fair value uplift and cash conversion ran at just 28.1% as working capital absorbed $12.3m.
Published 22 April 2026
Read briefingRecovery from the FY23 mortality event delivered a $36.4m EBITDA swing, but reported EBITDA of $18.5m sits well above pro-forma EBITDA of $10.7m.
Published 22 April 2026
Read briefingGet full NZX result briefings by email as new coverage is published.